SI-BONE (SIBN) Expected to Announce Earnings on Monday

SI-BONE (NASDAQ:SIBN) is expected to be releasing its Q1 2025 earnings data after the market closes on Monday, May 5th. Analysts expect SI-BONE to post earnings of ($0.24) per share and revenue of $45.13 million for the quarter. SI-BONE has set its FY 2025 guidance at EPS.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $49.00 million for the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, analysts expect SI-BONE to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-BONE Stock Performance

Shares of NASDAQ SIBN opened at $13.99 on Friday. SI-BONE has a 1 year low of $11.70 and a 1 year high of $19.16. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The stock has a market cap of $593.92 million, a PE ratio of -15.21 and a beta of 1.02. The firm has a fifty day moving average price of $14.61 and a 200-day moving average price of $14.66.

Insiders Place Their Bets

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,128 shares of the firm’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the transaction, the senior vice president now owns 244,878 shares of the company’s stock, valued at approximately $3,462,574.92. This trade represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Anthony J. Recupero sold 3,311 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the sale, the insider now directly owns 284,555 shares in the company, valued at $4,026,453.25. This trade represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,112 shares of company stock worth $101,275 over the last 90 days. Company insiders own 3.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Truist Financial reissued a “buy” rating and issued a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Needham & Company LLC raised their price objective on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $24.40.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.